
Halozyme Therapeutics Proposes $1.05 Billion Convertible Note Offering
Halozyme Therapeutics is seeking to raise $1.05 billion through an offering of convertible senior notes due 2033. The San Diego-based biopharmaceutical firm plans to use the capital to repurchase existing debt and fund capped call transactions, alongside general corporate purposes, subject to market conditions and final pricing negotiations.


























